Literature DB >> 28955386

Effects of Ticagrelor on Myocardial Infarct Size.

Joo-Yong Hahn1.   

Abstract

Entities:  

Year:  2017        PMID： 28955386      PMCID： PMC5614944          DOI： 10.4070/kcj.2017.0161

Source DB:  PubMed          Journal:  Korean Circ J        ISSN： 1738-5520            Impact factor:   3.243


× No keyword cloud information.
  9 in total

1.  Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.

Authors:  Yumei Ye; Gilad D Birnbaum; Jose R Perez-Polo; Manjyot K Nanhwan; Sven Nylander; Yochai Birnbaum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

2.  Ticagrelor Versus Clopidogrel on Myocardial Infarct Size in Patients Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Eun Kyoung Kim; Taek Kyu Park; Jeong Hoon Yang; Young Bin Song; Jin-Ho Choi; Seung-Hyuk Choi; Woo Jung Chun; Yeon Hyeon Choe; Hyeon-Cheol Gwon; Joo-Yong Hahn
Journal:  J Am Coll Cardiol       Date:  2017-04-25       Impact factor: 24.094

3.  Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Authors:  Dimitrios Alexopoulos; Ioanna Xanthopoulou; Vassilios Gkizas; George Kassimis; Konstantinos C Theodoropoulos; George Makris; Nikolaos Koutsogiannis; Anastasia Damelou; Grigorios Tsigkas; Periklis Davlouros; George Hahalis
Journal:  Circ Cardiovasc Interv       Date:  2012-11-20       Impact factor: 6.546

4.  ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.

Authors:  Paul W Armstrong; Hany Siha; Yuling Fu; Cynthia M Westerhout; Ph Gabriel Steg; Stefan K James; Robert F Storey; Jay Horrow; Hugo Katus; Peter Clemmensen; Robert A Harrington; Lars Wallentin
Journal:  Circulation       Date:  2011-12-16       Impact factor: 29.690

5.  Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.

Authors:  Robert F Storey; Steen Husted; Robert A Harrington; Stanley Heptinstall; Robert G Wilcox; Gary Peters; Mark Wickens; Håkan Emanuelsson; Paul Gurbel; Peer Grande; Christopher P Cannon
Journal:  J Am Coll Cardiol       Date:  2007-10-23       Impact factor: 24.094

6.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

7.  Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.

Authors:  Manjyot K Nanhwan; Shukuan Ling; Monica Kodakandla; Sven Nylander; Yumei Ye; Yochai Birnbaum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-07-10       Impact factor: 8.311

8.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

Authors:  Steen Husted; Håkan Emanuelsson; Stan Heptinstall; Per Morten Sandset; Mark Wickens; Gary Peters
Journal:  Eur Heart J       Date:  2006-02-13       Impact factor: 29.983

9.  Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.

Authors:  Jamal N Khan; John P Greenwood; Sheraz A Nazir; Florence Y Lai; Miles Dalby; Nick Curzen; Simon Hetherington; Damian J Kelly; Daniel Blackman; Charles Peebles; Joyce Wong; Marcus Flather; Howard Swanton; Anthony H Gershlick; Gerry P McCann
Journal:  J Am Heart Assoc       Date:  2016-05-31       Impact factor: 5.501
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.